EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

PRIMARY OBJECTIVES:

I. Correlate the level of EF5 binding with pre-treatment hemoglobin level and tumor grade and stage in patients undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer.

SECONDARY OBJECTIVES:

I. Correlate pre-treatment tumor hypoxia (as measured by EF5 binding) with time to progression and time to recurrence in these patients.

II. Correlate EF5 binding with CD-31 expression (tumor vasculature), Ki-67 expression (cellular proliferation), and erythropoietin signaling in these patients.

OUTLINE:

Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.

Patients are followed at 30-45 days after administration of EF5 and then every 3-6 months thereafter.

Inclusion criteria

• Histologically confirmed* diagnosis of 1 of the following:

• Cervical cancer
• Ovarian epithelial cancer
• Endometrial cancer
• Peritoneal cavity cancer
• Requires surgery or biopsy for diagnosis or as standard initial treatment for the tumor
• Performance status - ECOG 0-2
• WBC ≥ 2,000/mm^3
• Platelet count ≥ 100,000/mm^3
• Bilirubin normal
• Creatinine normal
• Creatinine clearance ≥ 60 mL/min
• No significant cardiac condition that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 month after study participation
• Weight ≤ 130 kg
• No other significant medical condition that would preclude study participation
• No scheduled chemotherapy for the tumor within the past 3 months
• No scheduled radiotherapy to the tumor within the past 3 months
• No other concurrent investigational agents